MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER (meropenem and sodium chloride) by B. Braun is 12. Approved for complicated skin, skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes and 14 more indications. First approved in 2015.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
Meropenem and Sodium Chloride in Duplex Container is an intravenous carbapenem antibiotic combination for hospital-based treatment of serious gram-negative and gram-positive infections. It treats complicated skin/skin structure infections, intra-abdominal infections, and bacterial meningitis through inhibition of bacterial cell wall synthesis. The duplex container format provides ready-to-use convenience, reducing preparation time in acute care settings.
Product is in peak commercial lifecycle; B. Braun maintains active hospital-focused distribution and antimicrobial stewardship positioning.
12.1 Mechanism of Action Meropenem is an antibacterial drug [see ]. 12.2 Pharmacodynamics The percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best…
Worked on MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moRoles on this peak-lifecycle product focus on hospital-based sales execution, formulary advocacy, and antimicrobial stewardship partnerships in a stable, mature market. Career growth is incremental; advancement typically requires cross-functional rotation or transition to newer molecules or therapeutic areas.